Abstract
BackgroundMetabolic syndrome and/or its components have been demonstrated to be risk factors for several cancers. They are also found to influence survival in breast, colon and prostate cancer, but the prognostic value of metabolic syndrome in gastric cancer has not been investigated.MethodsClinical data and pre-treatment information of metabolic syndrome of 587 patients diagnosed with early stage gastric cancer were retrospectively collected. The associations of metabolic syndrome and/or its components with clinical characteristics and overall survival in early stage gastric cancer were analyzed.ResultsMetabolic syndrome was identified to be associated with a higher tumor cell differentiation (P = 0.036). Metabolic syndrome was also demonstrated to be a significant and independent predictor for better survival in patients aged >50 years old (P = 0.009 in multivariate analysis) or patients with proximal gastric cancer (P = 0.047 in multivariate analysis). No association was found between single metabolic syndrome component and overall survival in early stage gastric cancer. In addition, patients with hypertension might have a trend of better survival through a good control of blood pressure (P = 0.052 in univariate analysis).ConclusionsMetabolic syndrome was associated with a better tumor cell differentiation in patients with early stage gastric cancer. Moreover, metabolic syndrome was a significant and independent predictor for better survival in patients with old age or proximal tumors.
Highlights
Gastric cancer (GC) is the fourth most common cancer in men and fifth in women, about 10% of annual deaths from cancer are attributed to GC
As showed in table 1, there were no significant differences between patients with Metabolic syndrome (MetS) and without MetS in gender, age, T stage (AJCC, 7th), N stage (AJCC, 7th), tumor size, tumor location, type of operation
We further explored the effects of the control of MetS disorders on overall survival (OS) in early stage GC
Summary
Gastric cancer (GC) is the fourth most common cancer in men and fifth in women, about 10% of annual deaths from cancer are attributed to GC. Metabolic syndrome and/or its components have been demonstrated to be risk factors for several cancers. They are found to influence survival in breast, colon and prostate cancer, but the prognostic value of metabolic syndrome in gastric cancer has not been investigated
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
